Safety Protocols With JAK Inhibitors

Video content above in prompted by the following:

• Discuss the Measure Up 1 and 2 studies (upadacitinib) (Simpson 2022). Do you see similar results in patients who take upadacitinib in your practice? When do you recommend this treatment?
• At 52 weeks, 82.0% and 79.1% of patients taking 15 mg upadacitinib achieved EASI-75, in Measure Up 1 and 2 respectively.
• At 52 weeks, 84.9% and 84.3% of patients taking 30 mg upadacitinib achieved EASI-75, in Measure Up 1 and 2, respectively.
• The most common AEs were acne, cough, headache, herpes zoster, and creatine kinase elevation
• 4.5% of patients taking 15 mg upadacitinib withdrew due to AEs.
• 7.2% of patients taking 30 mg upadacitinib withdrew due to AEs.